Back

G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer

Robinson, J.; Flint, G.; Garner, I.; Galli, S.; Maher, T.; Kuimova, M.; Vilar, R.; McNeish, I.; Brown, R.; Keun, H. C.; Di Antonio, M.

2024-06-28 cancer biology
10.1101/2024.06.24.600010 bioRxiv
Show abstract

Epigenetic evolution is a common mechanism used by cancer cells to evade the therapeutic effects of drug treatment. In ovarian cancers, epigenetically-driven resistance may be responsible for a large number of late-stage patient deaths. Here, we describe the first investigation into the role of G-quadruplex (G4) DNA secondary structures in mediating epigenetic regulation in drug-resistant ovarian cancer cells. Through genome-wide mapping of G4s in paired drug-sensitive and drug-resistant cell lines, we find that increased G4 formation is associated with significant increase in gene expression, with high enrichment in signalling pathways previously established to promote drug-resistant states. However, in contrast to previous studies, the expression-enhancing effects of G4s were not found at gene promoters, but intergenic and intronic regions, indicating that G4s promote long-range transcriptional regulation in drug-resistant cells. Furthermore, we discovered that clusters of G4s (super-G4s) are associated with particularly high levels of transcriptional enhancement that surpass the effects of super-enhancers, which act as well established regulatory sites in many cancers. Finally, we demonstrate that targeting G4s with small molecules results in significant down-regulation of pathways associated with drug-resistance, which results in resensitisation of resistant cells to chemotherapy agents. These findings indicate that G4 structures are critical for the epigenetic regulatory networks of drug-resistant cells and may represent a promising target to treat drug-tolerant ovarian cancer.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
NAR Cancer
37 papers in training set
Top 0.1%
11.7%
2
Nature Communications
5641 papers in training set
Top 17%
10.8%
3
British Journal of Cancer
49 papers in training set
Top 0.2%
5.4%
4
Cell Reports
1498 papers in training set
Top 7%
5.4%
5
Clinical Epigenetics
60 papers in training set
Top 0.1%
5.4%
6
Nucleic Acids Research
1281 papers in training set
Top 5%
4.2%
7
Science Advances
1243 papers in training set
Top 8%
4.0%
8
Cancers
213 papers in training set
Top 2%
3.2%
9
iScience
1154 papers in training set
Top 7%
3.2%
50% of probability mass above
10
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
3.2%
11
Scientific Reports
3612 papers in training set
Top 39%
2.7%
12
Cell Reports Medicine
153 papers in training set
Top 1%
2.7%
13
Communications Biology
993 papers in training set
Top 8%
2.6%
14
Cancer Research Communications
51 papers in training set
Top 0.5%
2.4%
15
Redox Biology
70 papers in training set
Top 0.6%
2.1%
16
Cancer Research
130 papers in training set
Top 2%
1.9%
17
Cell Death & Disease
126 papers in training set
Top 2%
1.7%
18
Journal of Biological Chemistry
690 papers in training set
Top 6%
1.5%
19
eLife
5828 papers in training set
Top 55%
1.3%
20
Clinical Cancer Research
64 papers in training set
Top 2%
1.1%
21
npj Precision Oncology
53 papers in training set
Top 1%
1.1%
22
EMBO Reports
263 papers in training set
Top 6%
1.0%
23
Molecular Cancer Research
49 papers in training set
Top 1%
1.0%
24
Molecular Cancer Therapeutics
40 papers in training set
Top 0.8%
1.0%
25
International Journal of Cancer
49 papers in training set
Top 1%
1.0%
26
Advanced Science
286 papers in training set
Top 10%
0.8%
27
Epigenetics
50 papers in training set
Top 0.7%
0.8%
28
BMC Cancer
67 papers in training set
Top 2%
0.8%
29
Molecular Oncology
55 papers in training set
Top 2%
0.6%
30
npj Systems Biology and Applications
125 papers in training set
Top 3%
0.6%